Global Fludarabine Injections Market Size, Share, and Trends Analysis Report, By Application (Chronic Lymphocytic Leukemia, and Acute Myeloid Leukemia) and By End-user (Hospitals and Speciality Clinics), Forecast (2022-2028)

The global fludarabine injections market is anticipated to grow at a considerable CAGR 5% during the forecast period (2022-2028). Fludarabine injections are the purine analogoue and antineoplastic medications used for treating chronic lymphocytic leukemia and acute myeloid leukemia in adults. The major factor attributing to the growth of the global fludarabine injections includes the rising prevalence of chronic lymphocytic leukemia across the globe. According to the report published by the American Society of clinical oncology (ASCO) in January 2021, 21,250 people were diagnosed with chronic lymphocytic leukemia in the US in 2020. Among these, 13,040 were males and 8,210 were females. Around 4,320 mortalities were caused in the US in 2020 due to this disease. Thus, boosting the demand for fludarabine injections for the treatment of chronic lymphocytic leukemia.

Additionally, the application of fludarabine injections is also increasing in the treatment of acute myeloid leukemia. According to the report published by the ASCO in January 2021, around 1% of all cancer cases are acute myeloid leukemia. Around 20,240 people were diagnosed with acute myeloid leukemia in the US in 2020. Among these, around 11,230 were males and 9,010 were females. Around 11,400 mortalities were reported due to this disease in the US in 2020. Acute myeloid leukemia is the second most common type of leukemia in children and adults with around 31% of adults with leukemia affected by acute myeloid leukemia.

The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in September 2021, GeoVax Labs Inc. announced the acquisition of the clinical-stage program of PNP Therpeutics Inc. adding the license of “Gedeptin”, an orphan clinical drug program used for the treatment of head and neck cancer. The Gedeptin therapy is done by injecting three intra-tumoral injections of Gedeptin followed by fludarabine phosphate. This acquisition will expand the Immuno-Oncology pipeline of GeoVax Labs Inc.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Application
  • By End-user
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Teva Pharmaceuticals Industries Ltd., Pfizer Inc., Fresenius, Sagent M&C LLC, and Viatris Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Fludarabine Injections  Market Report by Segment

By Application

• Chronic Lymphocytic Leukemia
• Acute Myleoid Leukemia

By End-user

• Hospitals
• Speciality Clinics